诺泰生物(688076) - 2024 Q4 - 年度业绩

Financial Performance - In 2024, the company achieved total operating revenue of CNY 1,624,608,104.43, a year-on-year increase of 57.19%[6] - The net profit attributable to the parent company reached CNY 400,720,418.47, reflecting a growth of 145.94% compared to the previous year[6] - The basic earnings per share increased by 144.74% to CNY 1.86[6] - The company's operating profit rose by 141.02% to CNY 457,129,978.95, while total profit increased by 156.94% to CNY 444,840,255.45[6] - The net profit excluding non-recurring gains and losses was CNY 406,774,102.09, a 141.98% increase from the previous year[6] Asset and Equity Growth - Total assets at the end of 2024 amounted to CNY 5,091,144,152.97, up 43.52% from the beginning of the year[6] - The company's equity attributable to the parent company increased by 22.76% to CNY 2,664,273,279.71[6] Return on Investment - The return on equity (ROE) improved to 16.58%, an increase of 8.32 percentage points year-on-year[6] Business Strategy and Growth Drivers - The company attributed its revenue growth to its "time-leading, technology-leading" business philosophy and the expansion of its quality customer base[11] - The company emphasized the importance of its international BD team's capabilities in driving sales growth and expanding its customer base[12]